论文部分内容阅读
目的：评价血脂康的长期疗效与安全性。方法：对５２例持续服用血脂康（１．２ｇ／ｄ）半年以上的原发性高脂血症患者，进行血脂与安全性指标的监测。结果：５２例服药８，１６，２４周血清总胆固醇水平分别降低１９．７％，１８．０％及２０．０％；低密度脂蛋白胆固醇水平分别降低２７．５％，２５．３％与２７．２％；甘油三酯水平分别降低２７．０％，２９．２％和３１．６％；高密度脂蛋白胆固醇水平分别升高１５．１％，１５．０％及１５．７％。各指标与治疗前比较均有显著性差异（Ｐ＜０．００１～０．０１），但各指标不同时间的疗效对比均无明显差异（Ｐ＞０．０５）。服药半年患者耐受较好，无明显不良反应。检查体重、血压、心电图、血清谷丙转氨酶、尿素氮、肌酐、血糖等安全指标均无明显异常（Ｐ＞０．０５）。结论：服血脂康半年主要血脂指标已达到我国“血脂异常防治建议”的目标值水平，且疗效稳定、安全
Objective: To evaluate the long-term efficacy and safety of Xuezhikang. Methods: 52 patients with persistent hyperlipidemia (1.2g / d) for more than six months of primary hyperlipidemia, blood lipid and safety indicators were monitored. Results: Serum total cholesterol level of 52 patients decreased by 19.7%, 18.0% and 20.0% respectively at 8, 16 and 24 weeks, while low density lipoprotein cholesterol decreased by 27.5% and 25.3% respectively 27.2%; triglyceride levels decreased by 27.0%, 29.2% and 31.6%, respectively; and high-density lipoprotein cholesterol levels increased by 15.1%, 15.0% and 15.7%, respectively. There was significant difference between each index and before treatment (P <0.001 ~ 0.01), but there was no significant difference (P> 0.05) in the curative effect of each index between different time points. Half a year patients with better tolerance, no significant adverse reactions. Body weight, blood pressure, electrocardiogram, serum alanine aminotransferase, urea nitrogen, creatinine, blood glucose and other safety indicators were not significantly different (P> 0.05). Conclusion: The main blood lipid index of taking blood-qi-zang for half a year has reached the target value of “prevention and cure of dyslipidemia” in our country, and the effect is stable and safe